<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-S8BBF4Q0/dcd36062-f5ec-4e7d-a1ce-d0e02b82422c/PDF"><dcterms:extent>1417 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-S8BBF4Q0/ab10821a-8383-4d1b-a900-e0aa9df93c29/TEXT"><dcterms:extent>34 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-S8BBF4Q0"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2020</dcterms:issued><dc:creator>Bogataj, Marija</dc:creator><dc:creator>Felicijan, Tjaša</dc:creator><dc:creator>Grabnar, Iztok</dc:creator><dc:creator>Kerec Kos, Mojca</dc:creator><dc:creator>Kristl, Albin</dc:creator><dc:creator>Trontelj, Jurij</dc:creator><dc:creator>Vovk, Tomaž</dc:creator><dc:creator>Žakelj, Simon</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:71</dc:format><dc:format xml:lang="sl">str. 35-42</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:4897905</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-S8BBF4Q0</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">bioanalitika</dc:subject><dc:subject xml:lang="sl">biofarmacija</dc:subject><dc:subject xml:lang="sl">farmakokinetični procesi</dc:subject><dc:subject xml:lang="sl">Farmakokinetika</dc:subject><dc:subject xml:lang="sl">Klinična farmacija</dc:subject><dc:subject xml:lang="sl">modeli</dc:subject><dc:subject xml:lang="sl">procesi sproščanja</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Ali lahko z modeli napovemo usodo zdravila v telesu in optimiramo zdravljenje?| Can models predict the drug performance in vivo and optimise pharmacotherapy?|</dc:title><dc:description xml:lang="sl">In this article, the principle of biopharmaceutical processes is pursued: dissolution, absorption, distribution, metabolism and elimination. For the evaluation of these processes we use different models. First we describe the models used to evaluate drug dissolution in vitro and the models used to estimate absorption and permeability in vitro. The information thus obtained can be used to classify drugs according to the biopharmaceutical classification system and to predict the extent of their absorption. Then, the models for the evaluation of metabolism and the principles of pharmacokinetic-pharmacodynamic modelling are described. The basic goal of studying pharmacokinetic processes is to optimise the pharmacotherapy of patients, which can be in clinical practice further upgraded with clinical pharmacy services</dc:description><dc:description xml:lang="sl">V pričujočem članku sledimo poteku farmakokinetičnih procesov: sproščanje, absorpcija, porazdeljevanje, metabolizem in izločanje. Za ponazarjanje teh procesov uporabljamo različne modele. Najprej opisujemo modele za vrednotenje procesov sproščanja in modele za vrednotenje absorpcije oz. permeabilnosti in vitro. Na osnovi tako pridobljenih informacij lahko učinkovine razvrstimo v ustrezen razred biofarmacevtskega klasifikacijskega sistema in predvidimo obseg absorpcije. Sledijo modeli za vrednotenje metabolizma in na koncu predstavitev področja farmakokinetično-farmakodinamičnega modeliranja. Osnovni namen proučevanja farmakokinetičnih procesov je optimizacija farmakoterapije bolnikov, ki jo v klinični praksi lahko nadgradimo s storitvami klinične farmacije</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-S8BBF4Q0"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-S8BBF4Q0" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-S8BBF4Q0/dcd36062-f5ec-4e7d-a1ce-d0e02b82422c/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-S8BBF4Q0/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-S8BBF4Q0" /></ore:Aggregation></rdf:RDF>